苯哌利多结构式
|
常用名 | 苯哌利多 | 英文名 | Benperidol |
|---|---|---|---|---|
| CAS号 | 2062-84-2 | 分子量 | 381.44 | |
| 密度 | 1.2±0.1 g/cm3 | 沸点 | N/A | |
| 分子式 | C22H24FN3O2 | 熔点 | N/A | |
| MSDS | N/A | 闪点 | N/A |
苯哌利多用途苯哌利多是一种相对古老的抗精神病药物。苯哌利多是一种丁丙酚类抗精神病药,在D2受体阻断方面具有最高的抗精神病效力[1]。 |
| 中文名 | 苯哌利多 |
|---|---|
| 英文名 | Benperidol |
| 中文别名 | 苯哌啶 | 1-{1-[4-(4-氟苯基)-4-氧代丁基]哌啶-4-基}-1H-苯并[d]咪唑-2(3h)-酮 | 3-[1-[4-(4-氟苯基)-4-氧代丁基]哌啶-4-基]-1H-苯并咪唑-2-酮 |
| 英文别名 | 更多 |
| 密度 | 1.2±0.1 g/cm3 |
|---|---|
| 分子式 | C22H24FN3O2 |
| 分子量 | 381.44 |
| 精确质量 | 381.185242 |
| PSA | 58.10000 |
| LogP | 4.09 |
| InChIKey | FEBOTPHFXYHVPL-UHFFFAOYSA-N |
| SMILES | O=C(CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 |
| 蒸汽压 | 7.96E-17mmHg at 25°C |
| 折射率 | 1.595 |
| 计算化学 | 1.疏水参数计算参考值(XlogP):无 2.氢键供体数量:1 3.氢键受体数量:4 4.可旋转化学键数量:6 5.互变异构体数量:4 6.拓扑分子极性表面积:52.6 7.重原子数量:28 8.表面电荷:0 9.复杂度:556 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
|
~%
苯哌利多 2062-84-2 |
| 文献:US3936468 A1, ; |
| 苯哌利多上游产品 2 | |
|---|---|
| 苯哌利多下游产品 0 | |
|
Radiation dosimetry of N-([11C]methyl)benperidol as determined by whole-body PET imaging of primates.
Eur. J. Nucl. Med. Mol. Imaging 35(4) , 771-8, (2008) N-([(11)C]methyl)benperidol ([(11)C]NMB) can be used for positron emission tomography (PET) measurements of D(2)-like dopamine receptor binding in vivo. We report the absorbed radiation dosimetry of i... |
|
|
Radiation dosimetry of [18F] (N-methyl)benperidol as determined by whole-body PET imaging of primates.
Nucl. Med. Biol. 24(4) , 311-8, (1997) Radiation absorbed doses due to IV administration of [18F](N-methyl) benperidol ([18F]NMB) were estimated by whole-body PET imaging of nonhuman primates. Time-activity curves were obtained for nine co... |
|
|
Validation of the reference tissue model for estimation of dopaminergic D2-like receptor binding with [18F](N-methyl)benperidol in humans.
Nucl. Med. Biol. 35(3) , 335-41, (2008) Positron emission tomography measurements of dopaminergic D2-like receptors may provide important insights into disorders such as Parkinson's disease, schizophrenia, dystonia and Tourette's syndrome. ... |
| 1-[1-[4-(p-Fluorophenyl)-4-oxobutyl]piperidin-4-yl]-2-benzimidazolinone |
| R 4584 |
| 1-[1-[3-(p-fluorobenzoyl)propyl]-4-piperidyl]-2-benzimidazolinone |
| EINECS 218-172-2 |
| 1-[1-[4-(4-Fluorophenyl)-4-oxobutyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one |
| 1-{1-[4-(4-Fluorophenyl)-4-oxobutyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one |
| Frenactil |
| Benzeridol |
| Benperidol |
| MFCD00866672 |
| Glianimon |
| Anquil |
| Frenactyl |
| 8089c.b. |
| Concilium |
| 1-{1-[4-(4-Fluorophenyl)-4-oxobutyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one |